Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Q-linea AB (publ)    QLINEA   SE0011527845

Q-LINEA AB (PUBL)

(QLINEA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Stockholm
01/21/2021 01/22/2021 01/25/2021 01/26/2021 01/27/2021 Date
157.5(c) 159.5(c) 160.5(c) 157(c) 151(c) Last
10 314 9 733 14 960 12 499 16 904 Volume
+2.61% +1.27% +0.63% -2.18% -3.82% Change
More quotes
Financials
Sales 2020 1,00 M 0,12 M 0,12 M
Net income 2020 -225 M -26,9 M -26,9 M
Net cash position 2020 160 M 19,1 M 19,1 M
P/E ratio 2020 -17,7x
Yield 2020 -
Sales 2021 93,4 M 11,2 M 11,2 M
Net income 2021 -200 M -23,9 M -23,9 M
Net Debt 2021 168 M 20,1 M 20,1 M
P/E ratio 2021 -20,6x
Yield 2021 -
Capitalization 4 078 M 488 M 487 M
EV / Sales 2020 3 919x
EV / Sales 2021 45,5x
Nbr of Employees 100
Free-Float 91,1%
More Financials
Company
Q linea AB is a Sweden-based medical technology company. The Company develops and manufactures in-vitro diagnostic (IVD) solutions for infectious diseases. The Company's core product candidate is ASTar, a fully-automated instrument for Antibiotic Susceptibility Testing (AST). It measures bacteria's antimicrobial susceptibility using the disposables developed by the Company. It is able to provide a susceptibility... 
More about the company
Notations Surperformance© of Q-linea AB (publ)
Trading Rating : Investor Rating :
More Ratings
All news about Q-LINEA AB (PUBL)
2020Q LINEA : initiates pivotal clinical study for ASTar
AQ
2020Q LINEA : Jonas Jarvius, CEO of Q-linea presents at Life Science Day
AQ
2020Q LINEA : develops portable blood culture technology
AQ
2020Q LINEA : Invitation to presentation of Q-linea's Interim report Q3-2020 on Nove..
AQ
2020WEBINAR TUESDAY NOVEMBER 10TH : Equal and better care for everyone
AQ
2020Q LINEA : enters into an agreement with Hvidovre Hospital as a participant in th..
AQ
2020Q LINEA : installs the first ASTar system at Uppsala University Hospital
AQ
2020Q LINEA PUBL : Interim report 1 january - 30 june 2020
AQ
2020Q LINEA PUBL : Invitation to presentation of Q-linea's Interim report Q2-2020 on..
AQ
2020Q LINEA PUBL : Change in the number of shares and votes in Q-linea AB
AQ
2020Q LINEA PUBL : linea has carried out a directed issue of 4 million shares, raisi..
AQ
2020Q LINEA PUBL : linea announces intention to carry out a directed share issue
AQ
2020Q LINEA PUBL : Bulletin from annual general meeting in q-linea ab (publ)
AQ
2020WEBINAR FRIDAY JUNE 5TH : How can we improve infection diagnostics with ASTar
AQ
2020Q LINEA PUBL : linea announces positive results from prospective study with ASTa..
AQ
More news
News in other languages on Q-LINEA AB (PUBL)

- No features available -

More news
Chart Q-LINEA AB (PUBL)
Duration : Period :
Q-linea AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends Q-LINEA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 172,50 SEK
Last Close Price 151,00 SEK
Spread / Highest target 15,9%
Spread / Average Target 14,2%
Spread / Lowest Target 12,6%
EPS Revisions
Managers and Directors
NameTitle
Jonas Sven Peter Jarvius President & Chief Executive Officer
Erika Elisabeth Kjellberg-Eriksson Chairman
Nils-Peter Kristensen Chief Operating Officer
Anders Lundin Chief Financial Officer & Head-Investor Relations
Tiziana di Martino Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
Q-LINEA AB (PUBL)-11.18%488
EXACT SCIENCES CORPORATION3.29%21 763
GUARDANT HEALTH, INC.14.36%14 735
BGI GENOMICS CO., LTD.31.71%9 694
INVITAE CORPORATION14.06%9 091
ADAPTIVE BIOTECHNOLOGIES CORPORATION-7.59%7 473